glp 1 peptides retatrutide Retatrutide: Comprehensive Safety and Clinical Data Retatrutide vs Tirzepatide (2026): Differences

Kumar A, Quraishi MN, Al-Hassi HO, et al

In the UK, NICE specifically recommends semaglutide (TA875) for adults with a BMI 35 kg/m (or 30 kg/m for certain ethnic groups) who have at least one weight-related comorbidity, with treatment limited to a maximum of 2 years

Research findings are available online in The Lancet Journal

Please consult your healthcare practitioner before using multiple patches simultaneously or outside of the recommended guidelines

I dont think it will displace oral Wegovy, but you should expect [its] growth to slow once competition enters the market. Far from cannibalizing the market, the new products are helping to grow it

doi: 10.1056/NEJMoa1509225 [DOI] [PubMed] [Google Scholar] 62